Literature DB >> 4205947

Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals.

K H Wong, J C Feeley, R S Northrup, M E Forlines.   

Abstract

The role of Vi antigen in human immunity against typhoid fever has been debated for decades. Circumstantial evidence indicates that Vi antigen may play a role in pathogenicity and immunity. A Vi preparation was isolated from Salmonella typhosa, the causative organism in human typhoid fever, by a mild precipitation method. It was significantly more potent in animal studies than preparations from Citrobacter used in the past for human study and less toxic than conventional typhoid vaccines. With this antigen, the role of Vi antigen in human protection is now being investigated.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4205947      PMCID: PMC414808          DOI: 10.1128/iai.9.2.348-353.1974

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Studies on infection and immunity in experimental typhoid fever. IV. Role of H antigen in protection.

Authors:  J G TULLY; S GAINES; W D TIGER TT
Journal:  J Infect Dis       Date:  1963 Mar-Apr       Impact factor: 5.226

2.  H antigen of Salmonella typhosa.

Authors:  J G TULLY; S GAINES
Journal:  J Bacteriol       Date:  1961-06       Impact factor: 3.490

3.  The VI antigens of the Enterobacteriaceae. I. Purification and chemical properties.

Authors:  E E BAKER; R E WHITESIDE; R BASCH; M A DEROW
Journal:  J Immunol       Date:  1959-12       Impact factor: 5.422

4.  Antigens of mycobacterial cell walls.

Authors:  K H Wong; M J Pickett; S Froman
Journal:  Infect Immun       Date:  1970-04       Impact factor: 3.441

5.  Studies on Vi antigen. II. Purification of Vi antigen from Escherichia coli 5395/38.

Authors:  M E WEBSTER; M LANDY; M E FREEMAN
Journal:  J Immunol       Date:  1952-08       Impact factor: 5.422

6.  Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal.

Authors:  R C Williams; R J Gibbons
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Role of the K88 antigen in the pathogenesis of neonatal diarrhea caused by Escherichia coli in piglets.

Authors:  G W Jones; J M Rutter
Journal:  Infect Immun       Date:  1972-12       Impact factor: 3.441

8.  Cell-mediated resistance induced with immunogenic preparations of Salmonella typhimurium.

Authors:  M R Venneman; L J Berry
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

9.  Determination of endotoxicity in bacterial vaccines.

Authors:  K H Wong; C E Miller; J C Feeley; Y K Chan
Journal:  Appl Microbiol       Date:  1973-03

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  10 in total

Review 1.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

2.  Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.

Authors:  J Y Wang; F R Noriega; J E Galen; E Barry; M M Levine
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

3.  Construction of a recombinant oral vaccine against Salmonella typhi and Salmonella typhimurium.

Authors:  Y Cao; Z Wen; D Lu
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

Authors:  S C Szu; X R Li; R Schneerson; J H Vickers; D Bryla; J B Robbins
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

5.  Vi antigen from Salmonella typhosa and immunity against typhoid fever. 11. Safety and antigenicity in humans.

Authors:  D M Levin; K H Wong; H Y Reynolds; A Sutton; R S Northrup
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

6.  Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi.

Authors:  C M Nolan; J C Feeley; P C White; E A Hambie; S L Brown; K H Wong
Journal:  J Clin Microbiol       Date:  1980-07       Impact factor: 5.948

7.  Production of Vi monoclonal antibodies and their application as diagnostic reagents.

Authors:  R S Tsang; P Y Chau
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

Review 8.  Typhoid fever & vaccine development: a partially answered question.

Authors:  Sandhya A Marathe; Amit Lahiri; Vidya Devi Negi; Dipshikha Chakravortty
Journal:  Indian J Med Res       Date:  2012       Impact factor: 2.375

9.  Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.

Authors:  Kun Xiong; Chunyue Zhu; Zhijin Chen; Chunping Zheng; Yong Tan; Xiancai Rao; Yanguang Cong
Journal:  Front Cell Infect Microbiol       Date:  2017-04-24       Impact factor: 5.293

10.  Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.

Authors:  Anu Kantele; Sari H Pakkanen; Riitta Karttunen; Jussi M Kantele
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.